GeoVax Labs Inc. is a clinical-stage biotechnology company. It engages in developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle based vaccine platform. GeoVax Labs Inc. is based in ATLANTA, GA.
Revenue (Most Recent Fiscal Year) | $0.08M |
Net Income (Most Recent Fiscal Year) | $-25.97M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | -- |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.45 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -- |
Net Margin (Trailing 12 Months) | -- |
Return on Equity (Trailing 12 Months) | -189.16% |
Return on Assets (Trailing 12 Months) | -140.10% |
Current Ratio (Most Recent Fiscal Quarter) | 2.24 |
Quick Ratio (Most Recent Fiscal Quarter) | 2.24 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $3.24 |
Earnings per Share (Most Recent Fiscal Quarter) | -- |
Earnings per Share (Most Recent Fiscal Year) | $-14.29 |
Diluted Earnings per Share (Trailing 12 Months) | $-13.34 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 2.31M |
Free Float | 2.22M |
Market Capitalization | $3.39M |
Average Volume (Last 20 Days) | 0.03M |
Beta (Past 60 Months) | 2.89 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 4.00% |
Percentage Held By Institutions (Latest 13F Reports) | 6.09% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |